In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $540.00. The company’s shares closed ...

Analyst Whitney Ijem from Canaccord Genuity maintained a Sell rating on Vertex Pharmaceuticals (VRTX – Research Report) and decreased the price target to $361.00 from $376.00. Whitney Ijem has ...

Vertex Pharmaceuticals (VRTX) closed at $476.37 in the latest trading session, marking a -0.28% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.27%.

As of October 28, 2024, Vertex Pharmaceuticals Incorporated had a $123.0 billion market capitalization, putting it in the 98th percentile of companies in the Biotechnology industry. Vertex ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Deep-pocketed investors have adopted a bullish approach towards Vertex Pharmaceuticals VRTX, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

VRTX will need to target hospitals and surgical centers as well as physicians' offices. Marketing will involve working with hospitals to gain formulary access through the Pharmacy & Therapeutics ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral ...

Average portfolio weight of all funds dedicated to VRTX is 0.51%, an increase of 5.07%. Total shares owned by institutions increased in the last three months by 1.10% to 287,243K shares.

UBS has resumed coverage of Vertex Pharmaceuticals (NASDAQ:VRTX) with a buy rating, citing the company's growth potential. The investment bank said it believes Vertex (VRTX) has “best in sector ...